Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Yang, Jun J., Cheng Cheng, Meenakshi Devidas, Xueyuan Cao, Dario Campana, Wenjian Yang, Yiping Fan, et al. “Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.” Blood 120, no. 20 (November 15, 2012): 4197–4204. https://doi.org/10.1182/blood-2012-07-440107.

Full Text

Tewari, Priti, Paul L. Martin, Adam Mendizabal, Suhag H. Parikh, Kristin M. Page, Timothy A. Driscoll, Harry L. Malech, Joanne Kurtzberg, and Vinod K. Prasad. “Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease.” Biol Blood Marrow Transplant 18, no. 9 (September 2012): 1368–77. https://doi.org/10.1016/j.bbmt.2012.02.002.

Full Text

Corbacioglu, Selim, Nancy Kernan, Leslie Lehmann, Joel Brochstein, Carolyn Revta, Stephan Grupp, Paul Martin, and Paul G. Richardson. “Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.” Expert Rev Hematol 5, no. 3 (June 2012): 291–302. https://doi.org/10.1586/ehm.12.18.

Full Text

Doby, Elizabeth H., Daniel K. Benjamin, Anne J. Blaschke, Robert M. Ward, Andrew T. Pavia, Paul L. Martin, Timothy A. Driscoll, Michael Cohen-Wolkowiez, and Cassandra Moran. “Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.” Pediatr Infect Dis J 31, no. 6 (June 2012): 632–35. https://doi.org/10.1097/INF.0b013e31824acc33.

Full Text

Hueckel, Rémi M., Jane M. Mericle, Karen Frush, Paul L. Martin, and Mary T. Champagne. “Implementation of condition help: family teaching and evaluation of family understanding.” J Nurs Care Qual 27, no. 2 (April 2012): 176–81. https://doi.org/10.1097/NCQ.0b013e318235bdec.

Full Text

Xu, Heng, Cheng Cheng, Meenakshi Devidas, Deqing Pei, Yiping Fan, Wenjian Yang, Geoff Neale, et al. “ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.” J Clin Oncol 30, no. 7 (March 1, 2012): 751–57. https://doi.org/10.1200/JCO.2011.38.0345.

Full Text

Richardson, Paul G., Angela R. Smith, Stephan A. Grupp, Nancy A. Kernan, Sally Arai, Paul R. Haut, Brandon M. Triplett, et al. “Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol.” In Blood, 118:226–27. AMER SOC HEMATOLOGY, 2011.

Scholars@Duke

Martin, Paul L., Joanne Kurtzberg, and Brett Hesse. “Umbilical cord blood: a guide for primary care physicians.” Am Fam Physician 84, no. 6 (September 15, 2011): 661–66.

Scholars@Duke

Driscoll, T. A., P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad, P. Szabolcs, and J. Kurtzberg. “Allogeneic transplantation for patients with high-risk or refractory neuroblastoma.” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 9552–9552. https://doi.org/10.1200/jco.2011.29.15_suppl.9552.

Full Text

Driscoll, T. A., P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad, P. Szabolcs, and J. Kurtzberg. “Allogeneic transplantation for patients with high-risk or refractory neuroblastoma.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 9552.

Scholars@Duke

Pages